Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson immunology Therapeutic Area Total — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, Q3 2026
4,221
Period ended Sep 30, 2026
Change on a year earlier
+1.3%
4,168 in Q3 2025
History
40 quarters
Since Q4 2016
Sources
32
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Immunology Therapeutic Area Total — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 4,221 | +1.3% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2026 | Jun 28, 2026 | 3,844 | -3.7% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2026 | Mar 29, 2026 | 3,380 | -8.8% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2025 | Dec 28, 2025 | 3,860 | -8.9% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2025 | Sep 28, 2025 | 4,168 | -9.8% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2025 | Jun 29, 2025 | 3,993 | -15.4% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2025 | Mar 30, 2025 | 3,707 | -12.7% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2024 | Dec 29, 2024 | 4,238 | -7.8% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2024 | Sep 29, 2024 | 4,621 | -4.7% | Form 10-Q (filed 2025-10-22) ↗ |
| Q2 2024 | Jun 30, 2024 | 4,722 | +5.0% | Form 10-Q (filed 2025-07-24) ↗ |
| Q1 2024 | Mar 31, 2024 | 4,247 | +3.3% | Form 10-Q (filed 2025-04-23) ↗ |
| Q4 2023 | Dec 31, 2023 | 4,595 | +11.6% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2023 | Oct 1, 2023 | 4,849 | +13.1% | Form 10-Q (filed 2024-10-23) ↗ |
| Q2 2023 | Jul 2, 2023 | 4,496 | +1.9% | Form 10-Q (filed 2024-07-25) ↗ |
| Q1 2023 | Apr 2, 2023 | 4,112 | -0.2% | Form 10-Q (filed 2024-05-01) ↗ |
| Q4 2022 | Jan 1, 2023 | 4,118 | -5.4% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2022 | Oct 2, 2022 | 4,287 | +0.9% | Form 10-Q (filed 2023-10-27) ↗ |
| Q2 2022 | Jul 3, 2022 | 4,411 | +4.3% | Form 10-Q (filed 2023-07-31) ↗ |
| Q1 2022 | Apr 3, 2022 | 4,119 | +5.2% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2021 | Jan 2, 2022 | 4,355 | +6.1% | Form 10-K (filed 2024-02-16) ↗ |
| Q3 2021 | Oct 3, 2021 | 4,250 | +12.2% | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2021 | Jul 4, 2021 | 4,231 | +20.1% | Form 10-Q (filed 2022-07-29) ↗ |
| Q1 2021 | Apr 4, 2021 | 3,914 | +7.6% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Jan 3, 2021 | 4,105 | +16.6% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2020 | Sep 27, 2020 | 3,789 | +2.1% | Form 10-Q (filed 2021-10-29) ↗ |
| Q2 2020 | Jun 28, 2020 | 3,523 | +1.6% | Form 10-Q (filed 2021-07-29) ↗ |
| Q1 2020 | Mar 29, 2020 | 3,638 | +11.9% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 29, 2019 | 3,522 | +5.4% | Form 10-K (filed 2022-02-17) ↗ |
| Q3 2019 | Sep 29, 2019 | 3,711 | +9.2% | Form 10-Q (filed 2020-10-23) ↗ |
| Q2 2019 | Jun 30, 2019 | 3,466 | +3.8% | Form 10-Q (filed 2020-07-24) ↗ |
| Q1 2019 | Mar 31, 2019 | 3,251 | +6.9% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 30, 2018 | 3,342 | +8.3% | Form 10-K (filed 2021-02-22) ↗ |
| Q3 2018 | Sep 30, 2018 | 3,398 | +3.9% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jul 1, 2018 | 3,338 | +12.8% | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2018 | Apr 1, 2018 | 3,042 | +3.8% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 3,086 | +5.1% | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2017 | Oct 1, 2017 | 3,269 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jul 2, 2017 | 2,959 | – | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2017 | Apr 2, 2017 | 2,930 | – | Form 10-Q (filed 2018-05-01) ↗ |
| Q4 2016 | Jan 1, 2017 | 2,936 | – | Form 8-K (a8k2017q4exhibit9915.htm, filed 2018-01-23) ↗ |
Breakdown
What makes up immunology therapeutic area total — worldwide sales ($m)
- Immunology Therapeutic Area Total — U.S. sales ($M)2,804 · Q3 2026
- Immunology Therapeutic Area Total — International sales ($M)1,417 · Q3 2026
- Immunology Therapeutic Area Total — Worldwide reported growth YoY (%)1.3% · Q3 2026
- Immunology Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)1.4% · Q3 2026
- TREMFYA (guselkumab) — Worldwide sales ($M)2,396 · Q3 2026
- STELARA (ustekinumab) — Worldwide sales ($M)716 · Q3 2026
- SIMPONI / SIMPONI ARIA (golimumab) — Worldwide sales ($M)568 · Q3 2026
- REMICADE (infliximab) — Worldwide sales ($M)394 · Q3 2026
- Other Immunology medicines — Worldwide sales ($M)147 · Q3 2026
Cite this data
StockData. (2026). Johnson & Johnson Immunology Therapeutic Area Total — Worldwide sales ($M) ($M), quarterly Q4 2016–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/ta_immunology
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.